FDA Approves Immunotherapy Drugs for Patients with Bladder Cancer

The FDA has approved four immunotherapy drugs—avelumab, atezolizumab, durvalumab, and pembrolizumab—for the treatment of patients with bladder cancer. All four drugs belong to a class of cancer therapies known as checkpoint inhibitors.

Cancer Currents: An NCI Cancer Research Blog